Enamine Ltd.

Using an extensive synthetic compound library, the companies plan to develop AI-based synthetic drugs. Credit: Enamine. AI drug discovery company Syntekabio has partnered with Ukraine-based global compound supplier Enamine for supply, synthesis of compounds and synthetic drug development. Under the Memorandum of Understanding (MOU) signed by the companies, the alliance will leverage an extensive synthetic compound library provided by Enamine to support drug candidate discovery services through Syntekabio’s AI platform, DeepMatcher. Syntekabio and Enamine will work at the AI Bio Supercomputer Center (ABS Center) in Daejeon, South Korea. Their aim is to derive optimised lead compounds for drug development, combining Syntekabio’s AI capabilities with Enamine’s chemical synthesis and preclinical biology services. The companies also plan joint marketing to accelerate their expansion in the global market for AI-driven drug discovery services. See Also: Novavax wins FDA emergency approval for updated Covid-19 vaccine Combating Pharmaceutical Crime with On-Dose Authentication Enamine is growing its global presence with branches in the US, Germany and Poland. Its comprehensive services include in vitro efficacy verification, binding assays and ADMET [absorption, distribution, metabolism, excretion and toxicity] screening. Enamine will apply its knowledge in chemical, custom synthesis and preclinical biology services to work with Syntekabio on therapeutic optimisation and extraction of lead compounds utilising the AI-based molecular design technology of Syntekabio. Syntekabio is also conducting bio-drug research using its NEO-ARS and Ab-ARS services. NEO-ARS is a personal and shared neoantigen prediction service. Ab-ARS focuses on new antibody discovery and optimisation research. Enamine business development director Dr Iaroslava Kos stated: “We are excited to collaborate with Syntekabio to integrate our extensive compound library with their advanced AI platform. “This partnership aims to accelerate the discovery of optimised lead compounds, enhancing the efficiency and effectiveness of drug development. By combining our strengths, we look forward to making significant advancements in the field of synthetic drug development.”

Access to compound collection enables greater flexibility and efficiencies in screening and target identification CAMBRIDGE, England & KYIV, Ukraine--(BUSINESS WIRE)-- Metrion Biosciences Limited (“Metrion”), the specialist ion channel and cardiac safety screening contract research organisation (CRO) and drug discovery company, and Enamine Ltd (“Enamine”), the global leader in supplying small molecules and early drug discovery services, announced that Metrion has enhanced its High Throughput Screening (HTS) services with the addition of access to Enamine’s compound libraries. The Enamine compound library collection is the largest in the world and includes both CNS and ion channel focused target libraries. The libraries can be split into discrete screening sets, enabling increased flexibility and efficiencies in screening and target identification. In addition, ‘analog-by-catalog’ from Enamine in-stock and ‘make-on-demand REAL libraries’ present a fast and economical solution for hit expansion and SAR (structure-activity relationships) studies. To ensure diversity and cost-efficiency, researchers can access specialist advice from Metrion’s team of ion channel and HTS experts to determine the most effective approach. The Company will also provide a Structured Data File of all libraries to compare against existing libraries, further increasing efficiency. Metrion’s HTS capabilities were launched in November 2022 as an addition to its extensive preclinical ion channel drug discovery and safety pharmacology services, to complement the Company’s automated and conventional electrophysiology services. Metrion’s HTS capabilities include 384 well screening via FLIPR Penta and Qube-384 systems. The services provide significant additional capacity and flexibility to support ion channel drug discovery projects for the Company’s global client base. Gary Clark, Director of Screening Technologies, Metrion Biosciences, said: “The combination of our specialist ion channel expertise with substantial HTS and hit-finding experience gives customers access to a dedicated team of drug discovery scientists, ensuring the correct strategic choices are made in compounds selected for screening. This additional access to the highest quality screening libraries from Enamine increases diversity and enables Metrion to maximise R&D budgets even more effectively.” Vladimir Ivanov, Executive Vice President, Enamine, commented: “Enamine is focused on delivering novel chemical compounds to support drug discovery. We are delighted that Metrion is adding access to our libraries to its HTS services offering. Enamine is also able to support subsequent steps of the discovery process including hit resupply, analoging from our in-stock and make-on-demand REAL libraries, and custom synthesis of advanced hits and leads.” View source version on businesswire.com: Contacts Katie Odgaard Zyme Communications E-mail: katie.odgaard@zymecommunications.com Source: Metrion Biosciences View this news release online at:

The partnership aims to champion innovative solutions for the early stages of the drug discovery process. The companies will focus on the development of revolutionary technology to facilitate the screening of ultra-large chemical spaces during the virtual screening process in drug discovery. Virtual screening involves searching libraries of small molecules to identify structures most likely to bind to a drug target. Vladimir Ivanov, Enamine’s executive vice president is enthusiastic about the collaboration, said: “Chemical space is countless, and we have developed an approach to its synthetically accessible parts like Enamine REAL Space. We are always happy to see an application of our make-on-demand compounds to speed up delivering new medicines.” Traditionally, virtual screening relied on generating 3D conformations of molecules and conducting computational processes on each conformation. However, this approach becomes impractical when screening ultra-large chemical spaces due to escalating storage costs. Achieves efficiency gains of over a hundredfold This is where Ignite, a virtual screening technology developed by Cresset comes in. The company says Ignite leverages knowledge of the construction of ultra-large chemical spaces, utilizing reagents as synthons and reactions to enable rapid screening. This innovative approach can achieve efficiency gains of over a hundredfold, enabling 3D virtual screening with modest resources. After successful development in a bespoke client library screening project, Cresset extended the technology to collaborate with Enamine. The technology has been applied to Enamine’s REAL Space, a library boasting over 38 billion make-on-demand molecules, currently the largest collection of commercially available compounds. googletag.cmd.push(function () { googletag.display('text-ad1'); }); Rob Scoffin, CEO of Cresset, highlighted the significance of the partnership, “Virtual screening on ultra-large chemical spaces is currently mostly performed using 2D methods. Ignite provides a novel strategy for fast 3D screening of billions of compounds, enabling our clients to access novel chemical starting materials for their research programs in collaboration with our Discovery CRO scientists.” To further explore these advancements, a collaborative webinar titled ‘New modalities for 3D virtual screening of ultra-large chemical spaces' is scheduled for March 5th, providing insights into the cutting-edge technology shaping the future of drug discovery.